6
54
7
↑6
↓54
—7
Evidence suggests Psilocybin maydecreaseDepression relief.
54 studies (67 claims)
Strong consensus
Typical effective dose 15 (1–25) mgacross 8 dosed studies
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| Psilocybin therapy | Decreases - consistently showed significant reductions in | depression | Human | cancer patients | Not specified in the abstract. | Evaluating the effectiveness of psilocybin in alleviating distress among cancer patients: A systematic review. |
| psilocybin therapy | No effect - anticipated FDA approval | depression disorders | Human | — | Not mentioned | The need for establishing best practices and gold standards in psychedelic medicine.cited 12× |
| psilocybin therapy | Decreases - improved to a clinically meaningful degree | Montgomery-Asberg Depression Rating Scale (MADRS) scores | Human | people with mild to moderate stage PD plus depression and/or anxiety | One 10 mg dose followed by one 25 mg dose, administered with psychotherapy. | Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial. |
| psilocybin therapy | Decreases - trended towards less optimism for a potential role | optimism for role in bipolar depression and emotionally unstable personality disorder | Human | consultant psychiatrists | Not mentioned | Amid magic and menace: psychiatrists' attitudes to psilocybin therapy. |
| psilocybin therapy | Decreases - resulted in a significant, sustained reduction | symptoms of depression | Human | clinicians after frontline work during the COVID-19 pandemic | 25 mg psilocybin orally in a single medication session. | Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial.cited 7× |
| psilocybin vs niacin | Decreases - mean difference between arms | symptoms of depression (MADRS scores) | Human | clinicians | 25 mg psilocybin orally in a single medication session. | Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial.cited 7× |
| psilocybin | Decreases - mean change in symptoms of depression (MADRS scores) | symptoms of depression | Human | clinicians | 25 mg psilocybin orally in a single medication session. | Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial.cited 7× |
| Oral psilocybin | Decreases - producing statistically significant reductions | depression and anxiety symptoms | Human | multiple clinical trials | Not mentioned | The Use of Psilocybin in the Treatment of Psychiatric Disorders with Attention to Relative Safety Profile: A Systematic Review.cited 19× |
| psychotherapy-assisted psilocybin applications | Decreases - opened new avenues in the treatment | life-threatening cancer-related anxiety and depression | Human | patients with life-threatening cancer | Not specified | Psychedelic therapy in depression and substance use disorders.cited 10× |
| psilocybin with mindfulness training | Decreases - may represent a promising treatment | depression and burnout | Human | physicians and nurses | 8-week MBSR curriculum (frequency not specified) plus a single 25mg psilocybin dose in the combined group. | Psilocybin-Assisted Group Psychotherapy + Mindfulness Based Stress Reduction (MBSR) for Frontline Healthcare Provider COVID-19 Related Depression and Burnout: A Randomized Clinical Trial. |
| psilocybin and MBSR | No effect - evaluate the safety and preliminary efficacy | symptoms of depression and burnout | Human | frontline healthcare providers related to the COVID-19 pandemic | 8-week MBSR curriculum (frequency not specified) plus a single 25mg psilocybin dose in the combined group. | Psilocybin-Assisted Group Psychotherapy + Mindfulness Based Stress Reduction (MBSR) for Frontline Healthcare Provider COVID-19 Related Depression and Burnout: A Randomized Clinical Trial. |
| psilocybin with psychological support | Decreases - effective at treating | depression, including treatment-resistant depression | Human | — | Not specified | Psychedelic medicines for mood disorders: current evidence and clinical considerations.cited 17× |
| Psilocybin and LSD | Decreases - reduced anxiety and depression | anxiety and depression | Human | cancer patients | Not specified | Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.cited 131× |
| methylphenidate or novel agents, such as ketamine or psilocybin | No effect - Existing evidence is inadequate to definitively recommend | cancer-related depression and pain | Human | patients with cancer pain and significant depression | Not specified | Depression and Long-Term Prescription Opioid Use and Opioid Use Disorder: Implications for Pain Management in Cancer.cited 15× |
| hallucinogens like lysergic acid diethylamide and psilocybin | Decreases - inducing substantial perceptual and cognitive shifts that facilitate deep psychological introspection and significant therapeutic advances | depression and anxiety disorders | Human | patients suffering from depression and anxiety disorders | Not specified | Psychoactive substances for the treatment of neuropsychiatric disorders.cited 2× |
| a single 25 mg oral dose of psilocybin | No effect - No significant differences were found | clinician rated depression | Human | medication discontinued versus unmedicated at screening groups | Single 25 mg oral dose of psilocybin. | Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation: Comparaison des effets antidépresseurs de la psychothérapie assistée par la psilocybine (PAP) chez les personnes non médicamentées à la sélection initiale et les personnes ayant arrêté les médicaments pour participer à l'étude. |
| a single 25 mg oral dose of psilocybin | No effect - No significant differences were found | self-reported depression | Human | medication discontinued versus unmedicated at screening groups | Single 25 mg oral dose of psilocybin. | Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation: Comparaison des effets antidépresseurs de la psychothérapie assistée par la psilocybine (PAP) chez les personnes non médicamentées à la sélection initiale et les personnes ayant arrêté les médicaments pour participer à l'étude. |
| psilocybin-assisted psychotherapy | Increases - Comparable improvements were observed | depression and anxiety and symptoms | Human | antidepressant discontinued and UAS patients | Single 25 mg oral dose of psilocybin. | Comparing Antidepressant Effects of Psilocybin-Assisted Psychotherapy in Individuals That Were Unmedicated at Initial Screening Versus Individuals Discontinuing Medications for Study Participation: Comparaison des effets antidépresseurs de la psychothérapie assistée par la psilocybine (PAP) chez les personnes non médicamentées à la sélection initiale et les personnes ayant arrêté les médicaments pour participer à l'étude. |
| high dose psilocybin | Decreases - was better than placebo | change in depression | Human | patients with depressive symptoms | Not specified for Ayahuasca. | Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis.cited 4× |
| high dose psilocybin | Decreases - relative effect was larger than escitalopram at 10 mg | change in depression | Human | patients with depressive symptoms | Not specified for Ayahuasca. | Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis.cited 4× |
| high dose psilocybin | Decreases - relative effect was larger than escitalopram at 20 mg | change in depression | Human | patients with depressive symptoms | Not specified for Ayahuasca. | Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis.cited 4× |
| COMP360 psilocybin | No effect - correlated with | depression response | Human | participants with treatment-resistant depression | Single doses of 25, 10, or 1 mg of COMP360 psilocybin | The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.cited 3× |
| COMP360 psilocybin (25 mg dose) | Decreases - correlated with | Week 3 change from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) score | Human | participants with treatment-resistant depression | Single doses of 25, 10, or 1 mg of COMP360 psilocybin | The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.cited 3× |
| COMP360 psilocybin (25 mg dose) | Decreases - correlated with | Week 3 change from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) score | Human | participants with treatment-resistant depression | Single doses of 25, 10, or 1 mg of COMP360 psilocybin | The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.cited 3× |
| COMP360 psilocybin (25 mg dose) | Decreases - correlated with | Week 3 change from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) score | Human | participants with treatment-resistant depression | Single doses of 25, 10, or 1 mg of COMP360 psilocybin | The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.cited 3× |
| ayahuasca, psilocybin and LSD | Decreases - suggest beneficial effects | anxiety and depression associated with life-threatening diseases | Human | patients | Not specified | Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.cited 163× |
| ayahuasca, psilocybin and LSD | Decreases - suggest beneficial effects | treatment-resistant depression | Human | patients | Not specified | Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.cited 163× |
| Psychedelic-assisted therapy (PAT) with substances like psilocybin and MDMA | Increases - has shown promise | conditions including depression and post-traumatic stress disorder | Human | — | Not mentioned | Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals.cited 1× |
| psilocybin-assisted therapy | Decreases - favouring | 1-week between-group change in depression ratings | Human | patients with major depressive disorder | Not specified in the abstract. | Randomized Controlled Trials of Psilocybin-Assisted Therapy in the Treatment of Major Depressive Disorder: Systematic Review and Meta-Analysis. |
| psilocybin-assisted therapy (PAT) | Decreases - decreases | depression | Human | patients with alcohol use disorder (AUD) | Two medication sessions (psilocybin or diphenhydramine), exact dosage not specified. | Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial.cited 3× |
| psilocybin-assisted therapy (PAT) | Decreases - has been suggested to have positive effects | depression and psychiatric distress | Human | patients suffering from depression and psychiatric distress associated with life-threatening disease | Not specified | CURRENT STATE OF PSILOCYBIN-ASSISTED THERAPY IN MOOD DISORDERS. |
| psilocybin-assisted therapy | Decreases - pooled standard mean difference | depressive symptoms measured by 17-Item Hamilton Depression Rating Scale | Human | adult patients with clinically diagnosed depression | Not specified | The association between diverse psychological protocols and the efficacy of psilocybin-assisted therapy for clinical depressive symptoms: a Bayesian meta-analysis.cited 2× |
| psilocybin-assisted therapy | Increases - have shown promising outcomes | efficacy, safety, tolerability, and durability for depression | Human | — | Not specified | Psychedelic-Assisted Therapy in Military and Veterans Healthcare Systems: Clinical, Legal, and Implementation Considerations.cited 5× |
| psilocybin-assisted therapy | Decreases - patients underwent remission after | major depressive disorder and treatment-resistant depression | Human | patients | Single 25 mg dose mentioned in the largest clinical trial. | Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin.cited 7× |
| psilocybin | Decreases - much smaller remission rate | depression | Human | more than 100 depressed participants in larger Phase II trials | Single 25 mg dose mentioned in the largest clinical trial. | Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin.cited 7× |
| psilocybin-assisted psychotherapy | Decreases - encouraging data supporting the use | depression | Human | adults with depression | Not specified | Therapeutic Potential of MDMA- and Psychedelic-Assisted Psychotherapy for Adolescent Depression and Trauma. |
| psilocybin | Decreases - has shown great potential for treatment | anxiety and depression | Human | — | Not specified | Sustained effects of single doses of classical psychedelics in humans.cited 28× |
| psilocybin | No effect - no adequately powered RCTs to support their use | BD depression | Human | — | Not specified | New Pharmacologic Approaches to the Treatment of Bipolar Depression.cited 6× |
| psilocybin (0.3 mg/kg dose) | Decreases - was the most effective | Beck Depression Inventory (BDI) | Human | cancer patients | 0.3 mg/kg (highest effective dose) | Psilocybin-assisted psychotherapy as a rapid-acting treatment for cancer-related depression and anxiety: Evidence from a network meta-analysis. |
| psilocybin | Decreases - significantly reduced | Beck Depression Inventory (BDI) scores | Human | cancer patients | 0.3 mg/kg (highest effective dose) | Psilocybin-assisted psychotherapy as a rapid-acting treatment for cancer-related depression and anxiety: Evidence from a network meta-analysis. |
| psilocybin | Decreases - showed efficacy | cancer-related depression | Human | patients with cancer-related depression | Single-dose (specific amount not mentioned). | The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.cited 33× |
| psilocybin | Decreases - demonstrated the efficacy in reducing symptom severity | depression | Human | — | Not specified | Narrative review of the potential for psychedelics to treat Prolonged Grief Disorder.cited 2× |
| psilocybin | Decreases - suggesting a rapid antidepressant effect sustained | depression | Human | some responders | Not specified | Psychedelics for treatment resistant depression: are they game changers?cited 5× |
| psilocybin | Decreases - highly promising preliminary data have been produced | depression | Human | — | Not specified | Psychedelic drugs-a new era in psychiatry? .cited 53× |
| psilocybin | No effect - merit rigorous replication studies | depression | Human | — | Not specified | Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money.cited 3× |
| psilocybin | Decreases - can be used as a fast-acting antidepressant | depression | Molecular | clinical and preclinical studies | Not specified. | Psilocybin and the glutamatergic pathway: implications for the treatment of neuropsychiatric diseases.cited 1× |
| psilocybin | Decreases - superior in treating depression | depression | Human | — | Not specified | Psilocybin for major depressive disorder: An updated systematic review and meta-analysis of randomized clinical trials.cited 2× |
| psilocybin | Decreases - addressing conditions | depression | Human | patients with chronic pain | Not specified | Psilocybin as a novel treatment for chronic pain. |
| psilocybin | Decreases - document the efficacy | depression | Human | patients with medically refractory depression | Not specified | Psilocybin as a Disease-Modifying Drug—A Salutogenic Approach in Psychiatry. |
| psilocybin | Decreases - revealed a strong effect | depression | Human | — | Not specified | Psilocybin as a Disease-Modifying Drug—A Salutogenic Approach in Psychiatry. |
| psilocybin | Decreases - moderately superior to controls at reducing | depression | Human | participants | Not specified | Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs. |
| psilocybin | Decreases - demonstrates significant reduction relative to controls | depression | Human | — | Not specified | Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs. |
| psilocybin | Decreases - effects were moderate and attenuated | depression reduction | Human | larger and better-controlled studies | Not specified | Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs. |
| psilocybin | Decreases - smaller studies evidenced stronger effects that favored | depression reduction | Human | — | Not specified | Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs. |
| psilocybin | No effect - remission rate is | depression | Human | participants | Not specified | Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview.cited 4× |
| psilocybin | Decreases - reduction | depression | Human | patients with terminal illness | Not specified | Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.cited 59× |
| Psilocybin | No effect - is a highly promising drug candidate for the treatment | depression and several other mental health conditions | Molecular | — | Not mentioned | Substrate recognition by the 4-hydroxytryptamine kinase PsiK in psilocybin biosynthesis.cited 1× |
| psilocybin | No effect - did not correlate with response | depression changes | Human | Veterans with severe treatment-resistant depression (TRD) | 25 mg of psilocybin (single dose). | Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - A first-in-kind open-label pilot study.cited 5× |
| psilocybin | Decreases - maintained response | Montgomery-Åsberg Depression Rating scale (MADRS) | Human | Veterans with severe treatment-resistant depression (TRD) | 25 mg of psilocybin (single dose). | Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - A first-in-kind open-label pilot study.cited 5× |
| psilocybin | Decreases - maintained remission | Montgomery-Åsberg Depression Rating scale (MADRS) | Human | Veterans with severe treatment-resistant depression (TRD) | 25 mg of psilocybin (single dose). | Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - A first-in-kind open-label pilot study.cited 5× |
| psilocybin | Decreases - met response criteria | Montgomery-Åsberg Depression Rating scale (MADRS) | Human | Veterans with severe treatment-resistant depression (TRD) | 25 mg of psilocybin (single dose). | Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - A first-in-kind open-label pilot study.cited 5× |
| psilocybin | Decreases - met remission criteria | Montgomery-Åsberg Depression Rating scale (MADRS) | Human | Veterans with severe treatment-resistant depression (TRD) | 25 mg of psilocybin (single dose). | Single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - A first-in-kind open-label pilot study.cited 5× |
| psilocybin | No effect - not antidepressant-like | depression-like behaviors | Animal | mice | 5 mg/kg (intraperitoneal) | Concurrent stress modulates the acute and post-acute effects of psilocybin in a sex-dependent manner.cited 1× |
| psilocybin (1 mg/kg) | No effect - did not alter | depression-like behaviours | Animal | both genotypes | 1 mg/kg (single dose). | Mice lacking the serotonin transporter do not respond to the behavioural effects of psilocybin.cited 1× |
| psilocybin | Decreases - linked to lower probability | depression remission | Human | — | Not provided. | Preliminary Evidence of Sleep Improvements Following Psilocybin Administration, and their Involvement in Antidepressant Therapeutic Action. |
| psilocybin (0.3 mg/kg) | Decreases - strongly associated with reductions | depression severity | Human | individuals with moderate to severe MDD | 0.3 mg/kg psilocybin (single dose). | Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial.cited 17× |
| psilocybin | No effect - assessed the safety and efficacy | major depression | Human | patients | Not specified | Psychedelic Medicines in Major Depression: Progress and Future Challenges.cited 5× |
| psilocybin | Decreases - produced immediate and significant anti-depressant and anxiolytic effects | symptoms of depression and anxiety | Human | patients with depression and/or anxiety | Not specified | Classical psychedelics for the treatment of depression and anxiety: A systematic review.cited 123× |
| psilocybin | No effect - support the efficacy | treatment of depression | Human | — | Not available. | Psychedelics and Psychedelic-Assisted Psychotherapy.cited 315× |
| psilocybin | No effect - designated as breakthrough therapy | treatment-resistant depression | Human | — | Not available. | Psychedelics and Psychedelic-Assisted Psychotherapy.cited 315× |
| psilocybin | Increases - best evidenced | treatment resistant depression | Human | patients | Not specified | Exploring psilocybin's role in mental health and palliative medicine: a path to improved well-being. |
| psilocybin | Decreases - supports its efficacy | treatment-resistant depression (TRD) | Human | — | Not specified | The Emergence of Psilocybin in Psychiatry and Neuroscience. |
| psilocybin | Increases - has shown positive results | treatment-resistant depression (TRD) | Human | — | Not specified | Efficacy, Safety, and Tolerability of Psychedelics in Treatment-Resistant Depression (TRD).cited 2× |
| A single high dose of psilocybin in combination with therapy | Decreases - was found to lower | symptoms of depression | Human | participants | Single high dose (exact amount not specified). | Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation. |